Alembic Pharma gets tentative USFDA nod for Efinaconazole tropical solution
Aleor Dermaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efinaconazole tropical solution, 10 %, Alembic Pharma said in a regulatory filing.
The solution is indicated for the tropical treatment on onychomycosis of the toenails. The tentatively approved product is therapeutically equivalent to the reference listed drug product Jubila tropical solution, 10%, of Bausch Health Americas.
Recent Posts
Experts Warn of Global Threat from Chronic Wasting Disease
Chronic Wasting Disease (CWD) is a highly contagious and fatal neurological disorder that affects deer,…
CDC Reschedules Vaccine Advisory Meeting to April 15-16
The Centers for Disease Control and Prevention (CDC) has announced a rescheduling of its vaccine…
India’s Specialty Chemicals Rebound, Pharma Exports Surge
India’s specialty chemicals industry and pharmaceutical exports continue to showcase resilience amid global uncertainties. As…
Gut Bacteria: The Hidden Key to Human Brain Evolution
The evolution of the human brain is one of the most fascinating topics in science.…
Obesity and Sleep Apnea: Warning Signs and Prevention Tips
Sleep apnea is a common yet serious sleep disorder that affects millions of people worldwide.…
Harmful Bacteria in the Human Body: Risks and Prevention
The human body is home to trillions of bacteria, many of which are beneficial for…